• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Volition signs exclusive license and supply agreement with Heska

March 30, 2022
dvm360 Staff

The $28 million agreement will allow Volition to distribute the Nu.Q Vet Cancer Screening test worldwide.

VolitionRx Limited (Volition)—a multinational epigenetic company announced it signed an exclusive global supply and license agreement with Heska Corporation (Heska)—a global provider of advanced veterinary diagnostics. Through the new agreement, Heska will receive exclusive worldwide rights to sell Volition’s Nu.Q Vet Cancer Screening test. According to the release, in exchange, Volition will receive a $10 million upfront payment on signing and up to $18 million based on milestone achievements near/mid-term.1

"We are thrilled to announce this agreement with Heska, a company dedicated to developing the next generation of rapid, highly affordable, point-of-care diagnostics for companion animals," expressed Tom Butera, DVM, chief executive officer of Volition Veterinary Diagnostics Development LLC, in the release.1

"We estimate the total addressable market worldwide for cancer screening and monitoring in canines and felines to be approximately $11 billion and growing. As such, we want to make our Nu.Q Vet Cancer Screening Test as accessible as possible to veterinarians around the world, ensure cancer is detected earlier, and improve outcomes for pets and pet owners," he explained

According to the release, Volition’s Nu.Q Vet Cancer Screening test will operate on Heska’s propriety point of care platform Element i+ Immunodiagnostic Analyzer.1 With this agreement, veterinarians will be able to screen pets for some of the most common cancers while providing crucial information to clients.

Advertisement

"The accurate, affordable, fast, and noninvasive Nu.Q Vet Cancer Screening Test is exactly such an innovation and is a perfect addition to our Heska test menu, which we believe is now the most complete, differentiated, and cutting-edge point of care diagnostics solutions stack available for pet healthcare professionals and pet families,” said Kevin Wilson, Heska's chief executive officer, and president.

“With the new Heska Nu.Q Vet Cancer Screening Test millions of pets will have access to critical cancer screening and monitoring instantly, and at the point of care, to catch, treat and drive recovery from cancers earlier and with much better healthcare outcomes and peace of mind,” he continued, in the release.

Reference

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care. News release. VolitionRx Limited. March 29, 2022. Accessed March 30, 2022. https://www.prnewswire.com/news-releases/volition-signs-exclusive-28-million-license-and-supply-agreement-with-heska-corporation-to-distribute-nuq-vet-cancer-screening-test-at-the-point-of-care-301512651.html

Related Content:

Business
Hiring employees in line with your brand
Hiring employees in line with your brand
Thriving when life is hard
Thriving when life is hard
Hospital design expert shares his favorite design element
Hospital design expert shares his favorite design element

Advertisement

Latest News

FDA approves first generic moxidectin injectable solution for cattle parasite treatment

UC Davis oral surgeons repair kitten’s severe left palate

Dermatology expert explains the PSPP system when dealing with ear disease

To refer or not to refer

View More Latest News
Advertisement